SG10201811185YA - Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii - Google Patents
Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viiiInfo
- Publication number
- SG10201811185YA SG10201811185YA SG10201811185YA SG10201811185YA SG10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA
- Authority
- SG
- Singapore
- Prior art keywords
- blood coagulation
- coagulation factor
- factor viii
- decrease
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014127240 | 2014-06-20 | ||
| JP2014226988 | 2014-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811185YA true SG10201811185YA (en) | 2019-01-30 |
Family
ID=54935230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811185YA SG10201811185YA (en) | 2014-06-20 | 2015-03-31 | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
| SG11201610581RA SG11201610581RA (en) | 2014-06-20 | 2015-03-31 | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610581RA SG11201610581RA (en) | 2014-06-20 | 2015-03-31 | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US20170253663A1 (fr) |
| EP (2) | EP4218816A3 (fr) |
| JP (2) | JP6663846B2 (fr) |
| KR (2) | KR20170015517A (fr) |
| CN (1) | CN106559987A (fr) |
| AU (1) | AU2015275440B2 (fr) |
| BR (1) | BR112016029316A2 (fr) |
| CA (1) | CA2951622C (fr) |
| IL (1) | IL249330B (fr) |
| MX (1) | MX2016016380A (fr) |
| MY (1) | MY189333A (fr) |
| RU (1) | RU2721910C2 (fr) |
| SG (2) | SG10201811185YA (fr) |
| TW (2) | TW201625299A (fr) |
| WO (1) | WO2015194233A1 (fr) |
| ZA (1) | ZA201700459B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006106905A1 (fr) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Procede pour la production de polypeptide au moyen de la regulation d’un ensemble |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| WO2016159213A1 (fr) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Procédé pour la production d'un hétéro-oligomère polypeptidique |
| EP3398965A4 (fr) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc |
| CN116059353A (zh) * | 2016-04-28 | 2023-05-05 | 中外制药株式会社 | 含抗体制剂 |
| JP7050677B2 (ja) * | 2016-07-29 | 2022-04-08 | 中外製薬株式会社 | 増強されたｆｖｉｉｉ補因子機能代替活性を有する二重特異性抗体 |
| EP3509637A4 (fr) | 2016-09-06 | 2020-05-27 | Chugai Seiyaku Kabushiki Kaisha | Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé |
| JP7051826B2 (ja) * | 2016-09-23 | 2022-04-11 | シーエスエル、リミテッド | 凝固因子結合タンパク質及びその使用 |
| US20210107994A1 (en) * | 2017-03-31 | 2021-04-15 | Public University Corporation Nara Medical University | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CA3071236A1 (fr) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Molecule multispecifique de liaison a l'antigene ayant une activite de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molecule en tant que principe actif |
| US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| LT3723858T (lt) | 2018-12-21 | 2022-02-10 | Kymab Limited | Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę |
| TW202207984A (zh) * | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 |
| MX2022003912A (es) | 2019-10-11 | 2022-04-20 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica. |
| KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
| KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
| KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1993012227A1 (fr) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Animaux transgeniques non humains capables de produire des anticorps heterologues |
| EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| EP0754225A4 (fr) | 1993-04-26 | 2001-01-31 | Genpharm Int | Animaux transgeniques capables de produire des anticorps heterologues |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| EP0823941A4 (fr) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Anticorps humains derives de xeno-souris immunisees |
| PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| CA2418835A1 (fr) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2005035754A1 (fr) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Anticorps a double specificite de substitution de proteine fonctionnelle |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| PL1876236T3 (pl) * | 2005-04-08 | 2015-01-30 | Chugai Pharmaceutical Co Ltd | Przeciwciała zastępujące czynność czynnika krzepnięcia VIII |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| CN103037893A (zh) * | 2010-06-14 | 2013-04-10 | 帕昂德国有限公司 | 具有纤溶亢进的凝血病的治疗 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
-
2015
- 2015-03-27 TW TW104109925A patent/TW201625299A/zh unknown
- 2015-03-27 TW TW110149549A patent/TWI831106B/zh active
- 2015-03-31 RU RU2017101705A patent/RU2721910C2/ru active
- 2015-03-31 MY MYPI2016704659A patent/MY189333A/en unknown
- 2015-03-31 KR KR1020177001413A patent/KR20170015517A/ko not_active IP Right Cessation
- 2015-03-31 CA CA2951622A patent/CA2951622C/fr active Active
- 2015-03-31 AU AU2015275440A patent/AU2015275440B2/en active Active
- 2015-03-31 JP JP2016529118A patent/JP6663846B2/ja active Active
- 2015-03-31 MX MX2016016380A patent/MX2016016380A/es unknown
- 2015-03-31 US US15/319,016 patent/US20170253663A1/en not_active Abandoned
- 2015-03-31 WO PCT/JP2015/060171 patent/WO2015194233A1/fr active Application Filing
- 2015-03-31 EP EP23157462.5A patent/EP4218816A3/fr active Pending
- 2015-03-31 KR KR1020247013296A patent/KR20240063162A/ko active Application Filing
- 2015-03-31 SG SG10201811185YA patent/SG10201811185YA/en unknown
- 2015-03-31 EP EP15809216.3A patent/EP3159006A4/fr not_active Withdrawn
- 2015-03-31 CN CN201580039806.4A patent/CN106559987A/zh active Pending
- 2015-03-31 SG SG11201610581RA patent/SG11201610581RA/en unknown
- 2015-03-31 BR BR112016029316-9A patent/BR112016029316A2/pt active Search and Examination
-
2016
- 2016-12-01 IL IL249330A patent/IL249330B/en unknown
-
2017
- 2017-01-19 ZA ZA2017/00459A patent/ZA201700459B/en unknown
-
2019
- 2019-06-05 US US16/432,790 patent/US20190309090A1/en not_active Abandoned
- 2019-12-16 JP JP2019226196A patent/JP2020055864A/ja active Pending
-
2020
- 2020-02-04 US US16/780,977 patent/US20200157243A1/en not_active Abandoned
- 2020-09-11 US US17/017,971 patent/US20200407463A1/en not_active Abandoned
-
2021
- 2021-04-20 US US17/235,445 patent/US20210238307A1/en not_active Abandoned
- 2021-11-24 US US17/534,566 patent/US20220073645A1/en not_active Abandoned
-
2022
- 2022-06-27 US US17/849,879 patent/US20220324999A1/en not_active Abandoned
-
2023
- 2023-02-06 US US18/164,709 patent/US20230174673A1/en not_active Abandoned
- 2023-10-02 US US18/479,149 patent/US20240052060A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| MX2019002510A (es) | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. | |
| TW201612167A (en) | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2021002321A (es) | Nuevos metodos. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
| UA96488U (uk) | Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця |